SAR422459
Gene therapy / editing
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01736592 NCT01736592 · Stargardt's Disease Registry: NCT01736592 | 2 | The incidence of Adverse Events (15 years) 2033-08-29 | In progress: results expected 29 Aug 2033 | not yet graded | link ↗ |
View 1 more trial
NCT01367444 NCT01367444 · Stargardt's Disease This open-label, non-randomized Phase 1/2a dose-escalation study gave subretinal SAR422459 gene therapy to 27 patients with Stargardt macular degeneration. Both registered primaries are treatment-emergent adverse event measures, with no comparator and no efficacy hypothesis. There is no met or missed result. Source: CT.gov posted results. Registry: NCT01367444 | 1/2 | Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) (From Baseline to Week 48); Percentage of Participants With TEAEs by Severity (From Baseline to Week 48) 2019-08-16 | Stopped early (terminated). Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow SAR422459 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.